News Sentiment

MIRM sentiment intelligence

Mirum Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 118.86 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

83/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-2.7% over one week, +10.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

Why (MIRM) Price Action Is Critical for Tactical Trading

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 83/100 classification
One-week reaction -2.7% Price reacting lower
Trend fit Trend active 10.9% over four weeks
Fair value 124.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 39
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Stock Titan 10
TradingView 6
simplywall.st 5
Moomoo 3
Investing.com 3
Trefis 3
Business Wire 2

Event Lens

What the news is about

Classified themes
Market update 40
Earnings 16
Analyst action 3
Deals and strategy 3
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 63
Stock Traders Daily Direct company coverage

Why (MIRM) Price Action Is Critical for Tactical Trading

This article analyzes Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) for tactical trading, highlighting a mid-channel oscillation pattern and a strong risk-reward short setup. It details institutional trading strategies, including long, breakout, and short positions, alongside multi-t

Tone
Negative 38/100
Event
Market update
Published
20 Jul 2026 02:41
Source
Stock Traders Daily
TradingView Direct company coverage

MIRM5806400 Bond Risk Profile

This article provides an overview of the MIRM5806400 bond issued by Mirum Pharmaceuticals, Inc. The bond has a 4.0% coupon and matures on May 1, 2029. It outlines key metrics for risk analysis, including security level, inflation protection, and issuer rating to help evaluate the

Tone
Neutral 50/100
Event
Analyst action
Published
16 Jul 2026 12:12
Source
TradingView
TradingView Direct company coverage

US604749AB7 Bond Profile — Key Metrics

This article provides key metrics for the Mirum Pharmaceuticals, Inc. 4.0% 01-MAY-2029 bond (US604749AB7). It details the issuer, issue and maturity dates, outstanding amount, face value, and coupon rate. Mirum Pharmaceuticals, Inc. is described as a biopharmaceutical company foc

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 04:10
Source
TradingView
Investing.com Nigeria Direct company coverage

Form 4 Mirum Pharmaceuticals Inc For: 8 July By Investing.com

This article reports on a Form 4 filing for Mirum Pharmaceuticals Inc related to activity on July 8th, as published by Investing.com. It is a brief announcement without further details, typical of stock market updates. The article also provides standard Investing.com market data,

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 19:09
Source
Investing.com Nigeria
Moomoo Direct company coverage

Mirum Pharmaceuticals Insider Sold Shares Worth $611,273, According to a Recent SEC Filing

An insider at Mirum Pharmaceuticals sold shares valued at $611,273 according to a recent SEC filing. This transaction indicates a significant insider sale, which is often monitored by investors for insights into a company's financial health and future prospects. Further details o

Tone
Negative 30/100
Event
Market update
Published
09 Jul 2026 18:10
Source
Moomoo
Stock Titan Direct company coverage

Mirum Pharmaceuticals (MIRM) CEO sells 20,000 shares after exercising options

Mirum Pharmaceuticals CEO Christopher Peetz exercised options for 20,000 shares and subsequently sold all 20,000 common shares in open-market transactions on July 6, 2026, as part of a pre-planned Rule 10b5-1 plan. The sale, valued at approximately $2.45 million, occurred at pric

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 06:39
Source
Stock Titan
Moomoo Direct company coverage

Mirum Pharmaceuticals Insider Sold Shares Worth $2,445,382, According to a Recent SEC Filing

An insider at Mirum Pharmaceuticals recently sold shares totaling $2,445,382, as disclosed in a recent SEC filing. This transaction indicates a significant insider sell-off. Further details would be needed to understand the context and potential implications of this sale.

Tone
Negative 28/100
Event
Market update
Published
09 Jul 2026 06:09
Source
Moomoo
GuruFocus Direct company coverage

Insider Sell Alert: Eric Bjerkholt Sells 5,000 Shares of Mirum P

Eric Bjerkholt, CFO of Mirum Pharmaceuticals Inc (MIRM), sold 5,000 shares on July 6, 2026, reducing his holdings to 42,181 shares. This sale is part of a trend of 40 insider sells against 1 insider buy over the past year for the company. The stock, trading at $122.25, is conside

Tone
Negative 29/100
Event
Market update
Published
09 Jul 2026 01:11
Source
GuruFocus
Investing.com Direct company coverage

Mirum Pharmaceuticals CEO Christopher Peetz sells $2.4 million in stock

Mirum Pharmaceuticals CEO Christopher Peetz sold 20,000 shares of the company's common stock for approximately $2.4 million on July 6, 2026, following the exercise of employee stock options. The sales occurred after a 155% surge in MIRM stock over the past year, with an Investing

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 21:11
Source
Investing.com
Stock Titan Direct company coverage

Mirum Pharmaceuticals (MIRM) CFO sells 5,000 shares under 10b5-1 plan

Mirum Pharmaceuticals' Chief Financial Officer, Eric Bjerkholt, sold 5,000 shares of common stock on July 6, 2026, through open-market transactions under a pre-arranged Rule 10b5-1 plan. The sales occurred at prices ranging from approximately $121.13 to $124.94 per share. Followi

Tone
Negative 39/100
Event
Market update
Published
08 Jul 2026 21:11
Source
Stock Titan
marketscreener.com Direct company coverage

RBC Capital Adjusts Mirum Pharmaceuticals Price Target to $148 From $142, Maintains Outperform Rating

RBC Capital has increased its price target for Mirum Pharmaceuticals (MIRM) to $148 from $142, while maintaining an Outperform rating on the stock. This adjustment reflects continued analyst confidence in the biopharmaceutical company, which focuses on treatments for rare liver d

Tone
Positive 67/100
Event
Analyst action
Published
07 Jul 2026 12:41
Source
marketscreener.com
Stock Titan Direct company coverage

Eric Bjerkholt reports sale of 5,000 MIRM shares (MIRM)

Eric Bjerkholt has reported the sale of 5,000 shares of Mirum Pharmaceuticals (MIRM) common stock on June 8, 2026, with a reported value of $469,073.00. This transaction was disclosed via a Form 144 filing, which is a routine notice for proposed sales of restricted securities. Th

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Christopher Peetz plans 20,000-share sale (NASDAQ: MIRM)

Christopher Peetz has filed a Form 144 indicating a proposed sale of 20,000 shares of Mirum Pharmaceuticals (NASDAQ: MIRM) common stock, which will be executed via a stock option exercise on July 6, 2026. The filing also reports a previous sale of 30,000 shares on June 1, 2026. T

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 20:39
Source
Stock Titan
Simply Wall Street Direct company coverage

FDA Priority Review For Zilurgisertib Could Be A Game Changer For Mirum Pharmaceuticals (MIRM)

Mirum Pharmaceuticals (MIRM) has received FDA priority review for zilurgisertib, a drug for fibrodysplasia ossificans progressiva, with a decision expected in late September 2026. This accelerated review and positive phase II results could significantly expand Mirum's rare diseas

Tone
Positive 72/100
Event
Earnings
Published
06 Jul 2026 18:10
Source
Simply Wall Street
TradingView Direct company coverage

Enterprise value to EBIT forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM

This article provides financial information for Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) on TradingView. It focuses on the company's enterprise value to EBIT forward metric. The content highlights the stock's market data and available financial tools on the platform.

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 05:39
Source
TradingView
Investing.com Direct company coverage

Mirum Pharmaceuticals SVP sells $326,520 in common stock

Jolanda Howe, Senior Vice President at Mirum Pharmaceuticals, sold 2,721 shares of the company's common stock for $326,520, with shares trading at $120.0 each. This sale occurred while the stock was near its 52-week high after a significant 156% gain over the past year, and was e

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 05:09
Source
Investing.com
Finviz Direct company coverage

MIRM - Mirum Pharmaceuticals Inc Latest SEC Filings

This article provides the latest SEC filing information for Mirum Pharmaceuticals Inc. (MIRM), offering a comprehensive overview of its financial performance, key valuation metrics, and stock market statistics. It details various financial ratios, insider and institutional owners

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 03:40
Source
Finviz
GuruFocus Direct company coverage

Insider Sell: Jolanda Howe Sells Shares of Mirum Pharmaceuticals Inc (MIRM)

Jolanda Howe, Senior Vice President, Global Controller at Mirum Pharmaceuticals Inc, sold 2,721 shares of the company on July 1, 2026, reducing her holdings to 3,114 shares. This transaction is part of a pattern of 39 insider sells against only 1 insider buy for MIRM over the las

Tone
Negative 35/100
Event
Market update
Published
03 Jul 2026 00:40
Source
GuruFocus
Stock Titan Direct company coverage

Mirum Pharmaceuticals (MIRM) SVP Howe sells 2,721 shares under 10b5-1 plan

Mirum Pharmaceuticals' SVP and global controller, Jolanda Howe, sold 2,721 shares of common stock at $120.00 per share in an open-market transaction. This sale, totaling $326,520, was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 18, 2026. Following the

Tone
Negative 35/100
Event
Market update
Published
02 Jul 2026 21:40
Source
Stock Titan
Simply Wall Street Direct company coverage

Mirum Pharmaceuticals (MIRM) Rallies On Trial News As Its Valuation Story Gets Harder To Ignore

Mirum Pharmaceuticals (MIRM) shares rallied 5.5% after positive phase II data and an FDA priority review for zilurgisertib, impacting its market value which now stands at US$7.3 billion. The stock has seen a strong uplift with a 25.05% return in 30 days and 54.30% year-to-date, p

Tone
Positive 74/100
Event
Market update
Published
02 Jul 2026 17:40
Source
Simply Wall Street
Investing.com Direct company coverage

Mirum Pharmaceuticals stock hits all-time high at 125.41 USD

Mirum Pharmaceuticals' stock reached an all-time high of $125.41, bringing its market capitalization to $7.6 billion, despite an InvestingPro analysis suggesting it might be overvalued. The company has seen a 147.06% increase over the last year and strong revenue growth of 50%. R

Tone
Positive 93/100
Event
Earnings
Published
02 Jul 2026 14:40
Source
Investing.com
Investing.com Canada Direct company coverage

Mirum Pharmaceuticals stock hits all-time high at 125.41 USD By Investing.com

Mirum Pharmaceuticals' stock reached an all-time high of $125.41, marking a 147.06% increase over the past year and bringing its market capitalization to $7.6 billion. Despite this, InvestingPro analysis suggests the stock might be overvalued relative to its Fair Value. The compa

Tone
Positive 78/100
Event
Market update
Published
02 Jul 2026 14:39
Source
Investing.com Canada
Market source Direct company coverage

The Bull Case For Mirum Pharmaceuticals (MIRM) Could Change Following Priority FDA Review Of FOP Drug Zilurgisertib

Mirum Pharmaceuticals recently reported positive phase II results for zilurgisertib in fibrodysplasia ossificans progressiva (FOP) and received FDA priority review. This development could reshape the investment narrative for Mirum, moving it beyond its reliance on Livmarli and st

Tone
Positive 73/100
Event
Earnings
Published
02 Jul 2026 09:14
Source
Market source
Investing.com Canada Direct company coverage

Form 144 MIRUM PHARMACEUTICALS For: 1 July By Investing.com

This article from Investing.com reports the filing of Form 144 for MIRUM PHARMACEUTICALS on July 1st. It provides the headline and mentions the stock symbol MIRM, along with a slight percentage increase. The article is very short and largely surrounded by extensive financial mark

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 03:39
Source
Investing.com Canada
Stock Titan Direct company coverage

2,721 performance shares proposed; Jolanda Howe sold 2,594 (MIRM)

A Form 144 filing by Morgan Stanley Smith Barney LLC Executive Financial Services discloses a proposed resale of 2,721 performance shares of Mirum Pharmaceuticals, Inc. (MIRM) dated March 15, 2026. The filing also reports that Jolanda Marie Howe previously sold 2,594 common share

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 21:39
Source
Stock Titan